• Dawonsys corrected a January loan-extension disclosure, citing termination of the loan following a sale of the related receivable.
• The final principal balance of the Dawon Medax loan receivable was set at KRW 23.4 billion, or 9.04% of equity.
• It signed an assignment agreement on Sept. 30 to sell the entire loan receivable to Core Value Partners for KRW 2.4 billion.
• Settlement is scheduled for Oct. 1, which will end the loan relationship; the company reported the loan balance as zero.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dawonsys Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930900704), on September 30, 2026, and is solely responsible for the information contained therein.